When large incumbents leave significant but challenging markets, leaner startups can leverage new technologies to drive change. As big pharmaceutical companies shy away from neurological disease research, Verge Genomics founder and CEO Alice Zhang describes how a confluence of technological advances in genomics is creating new opportunities. New nontraditional biotech companies, she observes, are being built by multidisciplinary teams fluent in both biology and computer science.